65. 原発性免疫不全症候群 Primary immunodeficiency Clinical trials / Disease details

臨床試験数 : 482 / 薬物数 : 653 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 212

13 trials found

diseases per page:

Showing 1 to 10 of 13 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04339777 (ClinicalTrials.gov)	September 22, 2020	8/4/2020	Allogeneic Hematopoietic Stem Cell Transplant for People With Primary Immunodeficiency Diseases	A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immunode ...	Lymphoproliferative Disorders;Autoimmune Lymphoproliferative;Immune System Diseases;Common Variable ...	Drug: Busulfan test dose;Drug: Fludarabine;Drug: Busulfan;Drug: Alemtuzumab;Radiation: Total body Irr ...	National Cancer Institute (NCI)	NULL	Suspended	4 Years	69 Years	All	10	Phase 2	United States
2	NCT03910452 (ClinicalTrials.gov)	October 28, 2019	9/4/2019	Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Bus ...	Haploidentical Transplant for Patients With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, B ...	Chronic Granulomatous Disease	Drug: Busulfan;Drug: Alemtuzumab;Drug: Cyclophosphamide;Drug: Sirolimus;Radiation: Total Body Irradi ...	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Suspended	4 Years	65 Years	All	4	Early Phase 1	United States
3	EUCTR2018-001489-41-SE (EUCTR)	02/07/2018	08/05/2018	A clinical trial using cell transplantation as treatment for bone marrow failure due to dyskeratosis ...	Radiation- and alkylator-free hematopoietic cell transplantation for bone marrow failure due to dysk ...	Dyskeratosis congenita / telomere disease MedDRA version: 20.0;Level: PT;Classification code 1000175 ...	Trade Name: Lemtrada INN or Proposed INN: Alemtuzumab Other descriptive name: ALEMTUZUMAB Trade Name: F ...	Karolinska Universitetssjukhuset	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - ( ...	United States;Sweden
4	NCT02162420 (ClinicalTrials.gov)	January 2015	10/6/2014	Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia	Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia	Dyskeratosis Congenita;Aplastic Anemia	Drug: Alemtuzumab;Drug: Fludarabine;Drug: Cyclophosphamide;Radiation: Total Body Irradiation;Biologi ...	Masonic Cancer Center, University of Minnesota	NULL	Recruiting	N/A	70 Years	All	50	N/A	United States
5	NCT01962415 (ClinicalTrials.gov)	February 4, 2014	10/10/2013	Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT	A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults =55 Years ...	Primary Immunodeficiency (PID);Congenital Bone Marrow Failure Syndromes;Inherited Metabolic Disorder ...	Drug: Hydroxyurea;Drug: Alemtuzumab;Drug: Fludarabine;Drug: Melphalan;Drug: Thiotepa	Paul Szabolcs	NULL	Recruiting	2 Months	55 Years	All	100	Phase 2	United States
6	NCT01821781 (ClinicalTrials.gov)	March 2013	19/3/2013	Immune Disorder HSCT Protocol	A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Immune Function Disorders Using a Reduc ...	Immune Deficiency Disorders;Severe Combined Immunodeficiency;Chronic Granulomatous Disease;X-linked ...	Drug: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan	Washington University School of Medicine	NULL	Recruiting	N/A	21 Years	All	20	Phase 2	United States
7	NCT01652092 (ClinicalTrials.gov)	September 4, 2012	25/7/2012	Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies	Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies	SCID;Omenn's Syndrome;Reticular Dysgenesis;Wiskott-Aldrich Syndrome;Bare Lymphocyte Syndrome;Common ...	Drug: Alemtuzumab 0.3 mg;Drug: Cyclophosphamide;Drug: Busulfan;Biological: Stem Cell Transplantation; ...	Masonic Cancer Center, University of Minnesota	NULL	Recruiting	N/A	50 Years	All	30	N/A	United States
8	NCT01659606 (ClinicalTrials.gov)	July 2012	6/8/2012	Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Con ...	Radiation- and Alkylator-free Hematopoietic Cell Transplantation for Bone Marrow Failure Due to Dysk ...	Dyskeratosis Congenita;Hoyeraal Hreidarsson Syndrome;Revesz Syndrome;Aplastic Anemia	Biological: alemtuzumab;Drug: Fludarabine;Drug: Cyclosporins;Drug: Mycophenolate mofetil	Boston Children's Hospital	Dana-Farber Cancer Institute;Children's Hospital Medical Center, Cincinnati;Children's Hospital Los ...	Recruiting	N/A	65 Years	All	40	Phase 2	United States;Norway;Sweden
9	NCT01182675 (ClinicalTrials.gov)	August 2010	9/8/2010	Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixa ...	Hematopoietic Stem Cell Transplantation for Children With Severe Combined Immunodeficiency Disease U ...	Severe Combined Immunodeficiency	Drug: Transplant Conditioning with Mobilization Only;Drug: Transplant Conditioning with Mobilization ...	University of California, San Francisco	NULL	Terminated	N/A	3 Years	All	7	Phase 2	United States
10	NCT00579137 (ClinicalTrials.gov)	October 2007	19/12/2007	Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders	CD45 and AlemtuzumabMonoclonal Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transpla ...	Severe Combined Immunodeficiency Disease;Severe Primary Immunodeficiency Disorder;Undefined T Cell D ...	Biological: Campath -1H;Drug: Fludarabine;Biological: Anti-CD45;Procedure: Stem cell infusion	Baylor College of Medicine	Center for Cell and Gene Therapy, Baylor College of Medicine;Texas Children's Hospital	Terminated	N/A	N/A	All	3	Phase 1/Phase 2	United States

First Previous1 2Next Last